Legal status in the United States
Is CagriSema legal?
Read at FDA, DEA and WADAPublished by PepVault
CagriSema has no FDA-approved product (it is in phase 3 trials), is not a federally controlled substance, and is not named on WADA’s Prohibited List (from January 1, 2027, its S0 class names peptides in general), as of November 18, 2026.
CagriSema at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Not approved; in phase 3 trials |
| Compounding | Barred from compounding (FDA) |
| DEA schedule | Not controlled |
| Sport (WADA) | Not named; from 2027, S0 names peptides in general |
FDA approval
CagriSema, cagrilintide combined with semaglutide, has no FDA-approved product: Drugs@FDA lists no application with cagrilintide in it. Semaglutide on its own is approved (Ozempic, Wegovy).
- Drugs@FDA data (openFDA): applications listing “CAGRILINTIDE” as an active ingredient, U.S. Food and Drug Administration. Read .
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026), U.S. Food and Drug Administration. Read .
In clinical trials
Novo Nordisk is testing CagriSema in phase 3 trials: ClinicalTrials.gov lists 9 active phase 3 studies of it, for obesity, type 2 diabetes, heart disease and high blood pressure.
- ClinicalTrials.gov record NCT07011667: A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term, ClinicalTrials.gov (National Library of Medicine). Read .

Compounding
FDA writes that cagrilintide, one of CagriSema’s two medicines, cannot be used in compounding under federal law.
The source: “Retatrutide and cagrilintide cannot be used in compounding under federal law.”
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
Until December 31, 2026: The 2026 Prohibited List doesn’t name cagrilintide, CagriSema or semaglutide. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name CagriSema, and whether S0 reaches it still turns on its approval outside the United States.
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
- World Anti-Doping Code International Standard, Prohibited List 2027 (comes into effect on January 1, 2027), World Anti-Doping Agency. Read .
- Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List, World Anti-Doping Agency. Read .
How it is sold when it isn’t approved
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.
The source: falsely labeled “for research purposes” or “not for human consumption.”
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026), U.S. Food and Drug Administration. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about CagriSema in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is CagriSema FDA approved?
CagriSema, cagrilintide combined with semaglutide, has no FDA-approved product: Drugs@FDA lists no application with cagrilintide in it. Semaglutide on its own is approved (Ozempic, Wegovy). Novo Nordisk is testing CagriSema in phase 3 trials: ClinicalTrials.gov lists 9 active phase 3 studies of it, for obesity, type 2 diabetes, heart disease and high blood pressure.
Is CagriSema a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is CagriSema banned in sport?
Until December 31, 2026: The 2026 Prohibited List doesn’t name cagrilintide, CagriSema or semaglutide. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name CagriSema, and whether S0 reaches it still turns on its approval outside the United States.
What does FDA say about compounding CagriSema?
FDA writes that cagrilintide, one of CagriSema’s two medicines, cannot be used in compounding under federal law.
What does FDA say about the “research use only” label?
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.